Inovio Stock Story

INO
 Stock
  

USD 2.59  0.13  5.28%   

Lets try to outline the odds of Inovio Pharma to fully recover from the latest slide as its shares went up 1.02%. The company current daily volatility is 6.0 percent, with a beta of 2.04 and an alpha of -0.33 over DOW. While many traders are getting carried away by overanalyzing aggressive defence, it is reasonable to outline Inovio Pharma. What exactly are Inovio Pharma shareholders getting in June?
Published over two months ago
View all stories for Inovio Pharma | View All Stories

Should you keep an eye on Inovio Pharma (NASDAQ:INO) management before June?

Inovio Pharma has roughly 394.94 M in cash with (229.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.88.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inovio Pharma has an asset utilization ratio of 3.05 percent. This suggests that the company is making $0.0305 for each dollar of assets. An increasing asset utilization means that Inovio Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Inovio Pharma, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Inovio Pharma along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inovio Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inovio Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inovio Pharma. Your research has to be compared to or analyzed against Inovio Pharma's peers to derive any actionable benefits. When done correctly, Inovio Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inovio Pharma.

How important is Inovio Pharma's Liquidity

Inovio Pharma financial leverage refers to using borrowed capital as a funding source to finance Inovio Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Inovio Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Inovio Pharma's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Inovio Pharma, but it might be worth checking our own buy vs. sell analysis

Inovio Pharma Correlation with Peers

Investors in Inovio can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Inovio Pharma. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Inovio Pharma and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Inovio is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Inovio for more details

Exercise or conversion by Simon Benito of 2000 shares of Inovio Pharma subject to Rule 16b-3

Legal trades by Inovio Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inovio insider trading alert for exercise of common stock options by Simon Benito, the corporate stakeholder, on 20th of July 2022. This event was filed by Inovio Pharmaceuticals In with SEC on 2022-07-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Inovio Pharma holds Efficiency (Sharpe) Ratio of -0.0904, which attests that the entity had -0.0904% of return per unit of risk over the last 3 months. Macroaxis standpoint towards determining the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Inovio Pharma exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to check out Inovio Pharma market risk adjusted performance of (0.32), and Risk Adjusted Performance of (0.15) to validate the risk estimate we provide.
AADI
ABCL
ABCM
ABEO
ABIO
AADI
0.750.690.82-0.31
AADI
ABCL
0.750.820.79-0.14
ABCL
ABCM
0.690.820.860.11
ABCM
ABEO
0.820.790.86-0.06
ABEO
ABIO
-0.31-0.140.11-0.06
ABIO
AADI
ABCL
ABCM
ABEO
ABIO
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Inovio showing proof of lower volatility

Latest variance is at 34.23. Inovio Pharma exhibits very low volatility with skewness of -1.36 and kurtosis of 5.19. However, we advise investors to further study Inovio Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inovio Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inovio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Inovio Pharma Implied Volatility

Inovio Pharma's implied volatility exposes the market's sentiment of Inovio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharma stock will not fluctuate a lot when Inovio Pharma's options are near their expiration.

Our Conclusion on Inovio Pharma

Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Inovio Pharma may offer a potential longer-term growth to institutional investors. To conclude, as of the 20th of May 2022, our analysis shows that Inovio Pharma hyperactively responds to market trends. The company is undervalued and projects quite high probability of distress for the next 2 years. Our primary 90 days 'Buy-vs-Sell' recommendation on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Inovio Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com